Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
Administration, Oral
Animals
Carbon-Sulfur Lyases
/ administration & dosage
Cell Proliferation
/ drug effects
Cisplatin
/ administration & dosage
Dose-Response Relationship, Drug
Female
Humans
Mice, Nude
Neoplasm Metastasis
Recombinant Proteins
/ administration & dosage
Tumor Burden
/ drug effects
Urinary Bladder Neoplasms
/ drug therapy
Xenograft Model Antitumor Assays
Bladder cancer
GFP
cisplatinum
combination
efficacy
nude mice
oral recombinant methioninase
orthotopic
sensitize
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
02
09
2020
revised:
09
09
2020
accepted:
15
09
2020
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
5
11
2020
Statut:
ppublish
Résumé
The aim of the study was to determine if oral recombinant methioninase (o-rMETase) can sensitize an orthotopic bladder tumor in nude mice to low-dose cisplatinum (CDDP). The green fluorescent protein (GFP)-expressing UM-UC-3-GFP bladder cancer was surgically orthotopically implanted (SOI) to the bladder in nude mice. The treatment was initiated when the primary tumor volume reached 100 mm The combination of o-rMETase and low-dose CDDP increased inhibition efficacy compared to low-dose CDDP monotherapy, on primary-tumor growth (p=0.032) and metastasis (p=0.002). The combination of o-rMETase with low-dose CDDP has future clinical potential for bladder cancer.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The aim of the study was to determine if oral recombinant methioninase (o-rMETase) can sensitize an orthotopic bladder tumor in nude mice to low-dose cisplatinum (CDDP).
MATERIALS AND METHODS
METHODS
The green fluorescent protein (GFP)-expressing UM-UC-3-GFP bladder cancer was surgically orthotopically implanted (SOI) to the bladder in nude mice. The treatment was initiated when the primary tumor volume reached 100 mm
RESULTS
RESULTS
The combination of o-rMETase and low-dose CDDP increased inhibition efficacy compared to low-dose CDDP monotherapy, on primary-tumor growth (p=0.032) and metastasis (p=0.002).
CONCLUSION
CONCLUSIONS
The combination of o-rMETase with low-dose CDDP has future clinical potential for bladder cancer.
Identifiants
pubmed: 33109546
pii: 40/11/6083
doi: 10.21873/anticanres.14629
doi:
Substances chimiques
Recombinant Proteins
0
Carbon-Sulfur Lyases
EC 4.4.-
L-methionine gamma-lyase
EC 4.4.1.11
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6083-6091Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.